演題抄録

臓器別シンポジウム

開催概要
開催回
第58回・2020年・京都
 

急性骨髄性白血病に対する遺伝子診断と分子標的治療

演題番号 : SY23-3

[筆頭演者]
山口 博樹:1 

1:日本医科大学・血液内科

 

In acute myeloid leukemia (AML), many chromosomal abnormalities and gene mutations involved in onset and recurrence were discovered by the recent progress of genome analysis technology. The founding not only have clinical application as prognostic factors and minimal residual disease markers, but also contribute to novel molecular targeted drug development. Many new drugs such as first-generation FLT3 inhibitor, IDH1/2 inhibitor and BCL2 inhibitor have been developed in Europe and United States. In addition, the second-generation FLT3 inhibitors, Gilteritinib and Quizartinib were developed in Japan, and treatment outcome of AML has been improved. However, there is still a large disparity in drug availability between the Europe and United States, and Japan. As a result, treatment guidelines in Europe and America cannot be applied to practical use in Japan. In this symposium, molecular target drug treatment by gene diagnosis will be considered for AML in present Japan, and the paradigm shift of gene diagnosis and treatment of AML in future will be outlined.

前へ戻る